Key facts
- Curve Biosciences’s last known valuation is $34.7M (May 2024).
- It has raised $56.0M across 1 recorded rounds; the latest was Early Stage VC ($17.7M) in May 2024.
- Notable investors include NZVC, Life Extension Ventures, First Spark Ventures, Civilization Ventures, Incite Ventures (San Francisco) — 10 tracked in total.
- Curve Biosciences has filed 1 Form D with the SEC, most recently May 2024 ($17.7M sold to 64 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Curve Biosciences
Funding rounds
1 roundsAbout Curve Biosciences
Developer of liver cancer diagnostics designed for disease prevention and screening. The company's patent-protected method helps with data structuring and mining methods and resolution assays to build tests and therapies, enabling healthcare professionals with technologies for diagnosis and treatment.
- Sector
- Healthcare
- HQ
- San Mateo, CA, United States
- Founded
- 2022
- Employees
- 26
- Website
- curvebio.com/
- Ownership
- Privately Held (backing)
Curve Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Curve Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Curve Biosciences in its N-PORT filings yet. We sweep new filings monthly.